FA
FAB.LSE Fusion Antibodies PLC
- Market cap
- GBX 7.51M
- P/E
- -
- P/B
- 4.63x
- ROE
- -70.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is FAB.LSE undervalued?
Graham numberThe Graham number of Fusion Antibodies PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fusion Antibodies PLC fundamental analysis
No fundamental analysis for Fusion Antibodies PLC yet.
Fusion Antibodies PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fusion Antibodies PLC
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing and engineering, antibody humanization and rational affinity maturation platform, recombinant protein expressions, and stable cel…
Full company profileFusion Antibodies PLC financial statements
Fusion Antibodies PLC annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.91M | 2.69M | 2.18M | 3.90M | 4.17M | 4.80M | 2.90M | 1.14M | 1.97M | 2.11M |
| Gross Profit | 961K | 1.48M | 804K | 1.15M | 1.31M | 1.72M | 202K | -265K | 430K | 1.10M |
| Operating Income | 127K | 62.4K | -1.51M | -1.11M | -1.38M | -1.33M | -2.83M | -2.29M | -1.78M | -1.98M |
| EBITDA | 288K | -637K | -1.06M | -431K | -532K | -573K | -2.48M | -2.06M | -1.62M | -1.85M |
| Net Income | 120K | -700K | -1.26M | -697K | -2.90M | -1.20M | -2.60M | -2.23M | -1.71M | -1.15M |
| EPS | 0.01 | -0.04 | -0.06 | -0.03 | -0.11 | -0.05 | -0.10 | -0.04 | -0.02 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 2.16M | 7.21M | 6.24M | 6.04M | 5.83M | 4.92M | 2.06M | 2.42M | 1.32M | 2.73M |
| Total Liabilities | 450K | 634K | 889K | 1.23M | 1.08M | 1.23M | 939K | 627K | 654K | 1.10M |
| Shareholders' Equity | 1.71M | 6.58M | 5.35M | 4.81M | 4.75M | 3.68M | 1.12M | 1.79M | 669K | 1.62M |
| Cash & Short-term Investments | 286K | 4.49M | 1.98M | 1.54M | 2.69M | 2.05M | 195K | 1.20M | 359K | 1.04M |
| Total Debt | - | 121K | 139K | 380K | 230K | 69.0K | 75.0K | 43.0K | 20.0K | 331K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -37.4K | 77.2K | -1.10M | -166K | -1.15M | -330K | -1.76M | -1.77M | -1.36M | -1.11M |
| Capital Expenditure | 90.3K | 445K | 1.38M | 109K | 365K | 258K | 114K | 2.00K | 10.0K | 60.0K |
| Free Cash Flow | -128K | -367K | -2.48M | -275K | -1.52M | -591K | -1.87M | -1.77M | -1.37M | -1.17M |
| Ratios | ||||||||||
| ROE | 7.0% | -10.6% | -23.6% | -14.5% | -61.1% | -32.6% | -231.2% | -124.1% | -256.1% | -70.8% |
| ROA | 5.6% | -9.7% | -20.3% | -11.5% | -49.7% | -24.4% | -125.9% | -92.0% | -129.5% | -42.1% |
| Net Profit Margin | 6.3% | -26.0% | -58.0% | -17.9% | -69.6% | -25.0% | -89.5% | -196.0% | -87.2% | -54.5% |
| Debt to Equity | - | 0.02x | 0.03x | 0.08x | 0.05x | 0.02x | 0.07x | 0.02x | 0.03x | 0.20x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Fusion Antibodies PLC dividends
Fusion Antibodies PLC has not paid dividends in the last 10 fiscal years.
Who owns Fusion Antibodies PLC
- Insiders 12.16%
- Institutions 29.00%
- Public & others 58.84%
- Shares outstanding 125M
- Free float 110M
Fusion Antibodies PLC company profile
- Company name
- Fusion Antibodies PLC
- Ticker
- FAB.LSE
- ISIN
- GB00BDQZGK16
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 27
- Fiscal year end
- March
- Address
- Springbank Industrial Estate, Belfast, United Kingdom, BT17 0QL
- Phone
- 44 28 9043 2800
- Website
- fusionantibodies.com
About Fusion Antibodies PLC
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing and engineering, antibody humanization and rational affinity maturation platform, recombinant protein expressions, and stable cell line development and cGMP scale up services. Its products are used in the pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company has a collaboration agreement with the National Cancer Institute for the use of OptiMAL. Fusion Antibodies plc was incorporated in 2000 and is based in Belfast, the United Kingdom.
Fusion Antibodies PLC management
3- Dr. Adrian Robert Kinkaid Ph.D.CEO & Director · born 1967
- Dr. Richard John Buick Ph.D.Chief Scientific Officer & Director · born 1976
- Mr. Stephen Barry SmythCompany Secretary, Interim CFO & Director · born 1974